Next week sees the start of the 2013 European Cancer Congress in Amsterdam.
ECCO have announced that King Willem-Alexander of the Netherlands will attend the opening ceremony, which is impressive.
Now that most of the meeting abstracts are available online we are starting to focus on what data may be hot at the meeting.
On Pharma Strategy Blog Sally Church, PhD has published her ECCO 2013 preview of late-breaking abstracts and those on PI3-kinase.
In addition to updates on PD-1 and PD-L1 data presented at ASCO, those that have attracted her attention include:
- T-DM1 for HER-2+ metastatic breast cancer
- Exploratory biomarker observations from the BOLERO-3 trial
- FLT1 gene variation in NSCLC
- Long-term survival data for ipilimumab in unresectable melanoma.
The PI3K-AKT-mTOR pathway is dysregulated in 80% cancers and Sally says it’s one of her favorite pathways. Ph1/2 data will be presented on GDC-0032, a next generation PI3K inhibitor.
Preliminary data showing early promise for GDC-0032 in breast cancer was presented at the 2013 AACR annual meeting.
You can read more about what may be interesting at the 2013 European Cancer Congress on Biotech Strategy Blog. Check it out! If you have plans to be in Amsterdam we hope to see you there.